Pure Global
NCT02112565

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
City of Hope Medical Center·Phase 1·ClinicalTrials.gov·drugActive, not recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
RNR inhibitor COH29
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
City of Hope Medical Center
Location
Duarte, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Jun 13, 2016
End date
Dec 31, 2023
Enrollment
12 participants
Primary outcome

Maximum tolerated dose of RNR inhibitor COH29, defined as the dose level with no more than 1 dose limiting toxicity (DLT) in the first 6 patients at a dose level below a dose level with DLT in 2 of 6 patients, graded according to CTCAE version 4.0

Summary

This phase I trial studies the side effects and best dose of RNR Inhibitor City of Hope 29
 (COH29) in treating patients with solid tumors that are refractory to standard therapy or for
 which no standard therapy exists. COH29 may inhibit an enzyme called ribonucleotide reductase
 and may interfere with the ability of tumor cells to grow.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02112565
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02112565 through Pure Global AI's free database. This Phase 1 trial is sponsored by City of Hope Medical Center and is currently Active, not recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.